$GKOS News
Last published 1d ago
- 1d agoGKOSStifel 2026 Healthcare Conference - GLAUKOS CORPEarnings Call TranscriptsOkay. Good morning, everyone. Tom Steffen with Stiefel. Welcome to the 2026 Stiefle Healthcare Conference. I'm excited to have Glaucos here with us today, coming off a very strong Q3 print. Joe, Alex, Chris, thanks so mu
- 1w agoSPGIKMBMGRCOKTA+5Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600PR NewswireNEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday,
- 2w agoGKOSGlaukos' Third Quarter 2026 Financial Results Conference Call - GLAUKOS CORPEarnings Call TranscriptsWelcome to Glaucus Corporation's 3rd Quarter 2026 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.g
- 2w agoGKOSGLAUKOS Corp - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoGKOSGlaukos Announces Third Quarter 2026 Financial ResultsBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial
- 1mo agoGKOSGlaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract SurgeryBusiness WireStudy Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority and Clinically Meaningful IOP Reduction vs. Cataract Surgery Alone iDose TR in Combination with Cataract Surgery Demonstrated
- 1mo agoGKOSGlaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal DiseasesBusiness WireLicense agreement also grants Glaukos exclusive rights to the RevMod™ platform for the discovery and development of up to four additional next-generation biologics for various retinal diseases Glaukos Corporation
- 1mo agoGKOSGlaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in KeratoconusBusiness WireThree-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment Glaukos Corporation (NYSE:GKOS), an
- 1mo agoGKOSGlaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28Business WireConference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal
- 1mo agoGKOSGlaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of KeratoconusBusiness WireNew Campaign Aims to Raise Awareness, Educate Patients and Families, and Promote Earlier Detection and Diagnosis Curry to Share His Personal Journey Living with Keratoconus to Empower Individuals to Prioritize
- 2mo agoGKOSGlaukos Announces Participation in Wells Fargo Healthcare ConferenceBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its
- 3mo agoGKOSGlaukos Announces Second Quarter 2026 Financial ResultsBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial
- 3mo agoGKOSGlaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShuntBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the
- 4mo agoGKOSGlaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Business WireConference Call and Webcast Scheduled for 1:30 p.m. PTGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal
- 4mo agoGKOSGlaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex BlepharitisBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion
- 4mo agoGKOSTRUIST SECURITIES MEDTECH CONFERENCE - Glaukos CorporationEarnings Call TranscriptsGood morning, everyone. I'm Rich Newiter, MedTech Analyst at Truist Securities. Thanks for joining us. Very lucky to have Glaucos Management, Alex Thurman, Chief Financial Officer, and Chris Lewis, Head of Investor Relat
- 5mo agoGKOSWilliam Blair 46th Annual Growth Stock Conference - GLAUKOS CORPEarnings Call TranscriptsMy name is Steve Lichtman. I'm the medical technology analyst here at William Blair, who covers our next presenter, Glaucus Corporation. Before we kick off the presentation, I'm required to inform you that for a complete
- 5mo agoGKOSGLAUKOS CORPORATION (GKOS) - STIFEL 2026 VIRTUAL OPHTHALMOLOGY FORUM - GLAUKOS CORPEarnings Call TranscriptsOkay, great. Good afternoon, everyone. Tom Steffen with Stiefel. Really excited to have Glaucos here with us today, participating again in the forum. Joe, Alex, Chris, great to see you guys. A lot to cover, have about 25
- 6mo agoGKOSGlaukos Announces Participation in Upcoming Investor ConferencesBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its
- 6mo agoGKOSGlaukos' First Quarter 2026 Financial Results Conference CallGLAUKOS CORPEarnings Call TranscriptsWelcome to Glowcoast Corporation's first quarter 2026 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at w
- 6mo agoGKOSGlaukos Announces First Quarter 2026 Financial ResultsBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial
- 6mo agoGKOSGlaukos Announces the Release of its 2025 Sustainability ReportBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has
- 7mo agoGKOSGlaukos Receives Permanent J-code for Epioxa™Business WireNew J-code for Epioxa™, J2789, set to become effective July 1, 2026 Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of
- 7mo agoGKOSGlaukos to Release First Quarter 2026 Financial Results after Market Close on April 29Business WireConference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal
- 7mo agoGKOSGlaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its
- 7mo agoGKOSGlaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus CareBusiness WireEpioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease Glaukos Corporation (NYSE:GKOS), an
- 8mo agoGKOSGlaukos' Fourth Quarter and Full Year 2025 Financial Results Conference CallGLAUKOS CORPEarnings Call TranscriptsHello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Gloucester's fourth quarter and full year 2025 Financial Results C
- 8mo agoGKOSGlaukos Announces Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial
- 9mo agoGKOSGlaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TRBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food
- 9mo agoGKOSApproval of Idose Tr, Nda #218010 (Labeling)FDA Approved DrugsApproval Date: 01/27/2026; Drug Name: Idose Tr, Nda #218010; Active Ingredients: TRAVOPROST; Company: Glaukos; Submission Status: Approval; Submission Classification: Labeling; Application Number: 218010
- 9mo agoGKOSApproval of Idose Tr, Nda #218010 (Efficacy)FDA Approved DrugsApproval Date: 01/27/2026; Drug Name: Idose Tr, Nda #218010; Active Ingredients: TRAVOPROST; Company: Glaukos; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 218010
- 9mo agoGKOSGlaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17Business WireConference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal
- 11mo agoGKOSGlaukos Announces Participation in J.P. Morgan Healthcare ConferenceBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its
- 1y agoGKOSGlaukos Announces Participation in Upcoming Investor ConferencesBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its
- 1y agoGKOSGlaukos Announces Third Quarter 2025 Financial ResultsBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial
- 1y agoGKOSGlaukos Announces FDA Approval of Epioxa™Business WireEpioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for Patients Afflicted
- 1y agoGKOSApproval of Epioxa Hd/epioxa Kit, Nda #219910 (Type 5 - New Formulation or New Manufacturer)FDA Approved DrugsApproval Date: 10/17/2025; Drug Name: Epioxa Hd/epioxa Kit, Nda #219910; Active Ingredients: RIBOFLAVIN 5'-PHOSPHATE; Company: Glaukos; Submission Status: Approval; Submission Classification: Type 5 - New Formulation or New Manufacturer; Application Number: 219910
- 1y agoGKOSApproval of Epioxa Hd, Nda #219910 (Type 3 - New Dosage Form and Type 4 - New Combination)FDA Approved DrugsApproval Date: 10/17/2025; Drug Name: Epioxa Hd, Nda #219910; Active Ingredients: RIBOFLAVIN5?-PHOSPHATE; Company: Glaukos; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form and Type 4 - New Combination; Application Number: 219910
- 1y agoGKOSApproval of , Nda #219910 (Type 3 - New Dosage Form and Type 4 - New Combination)FDA Approved DrugsApproval Date: 10/17/2025; Drug Name: , Nda #219910; Active Ingredients: undefined; Company: Glaukos; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form and Type 4 - New Combination; Application Number: 219910
- 1y agoGKOSApproval of Epioxa, Nda #219910 (Type 3 - New Dosage Form and Type 4 - New Combination)FDA Approved DrugsApproval Date: 10/17/2025; Drug Name: Epioxa, Nda #219910; Active Ingredients: RIBOFLAVIN5?-PHOSPHATE; Company: Glaukos; Submission Status: Approval; Submission Classification: Type 3 - New Dosage Form and Type 4 - New Combination; Application Number: 219910
- 1y agoGKOSGlaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual MeetingBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its
- 1y agoGKOSGlaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29Business WireConference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal
- 1y agoGKOSGlaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, AlabamaBusiness WirePlanned Investment of $80+ Million in 200,000 Square-Foot State-of-the-Art Facility Supports Glaukos' Long-Term Growth Plans and Reinforces Commitment to U.S. Manufacturing
- 1y agoGKOSGlaukos Announces Participation in Wells Fargo Healthcare ConferenceBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its
- 1y agoGKOSGlaukos Corporation (GKOS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoGKOSGlaukos Announces Second Quarter 2025 Financial ResultsBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial
- 1y agoGKOSGlaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30Business WireConference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal
- 1y agoGKOSGlaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS TherapiesBusiness WireRegulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework Glaukos
- 1y agoJBSGKOSNYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of recordPR NewswireThe New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for ...
- 1y agoGKOSGlaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing BellBusiness WireGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will